Ciclindole

Ciclindole (INN; WIN-27,147-2), also known as cyclindole (USAN), is an antipsychotic with a tricyclic structure that was never marketed.[1][2] It displaces spiperone binding in vitro and elevates dopamine levels in the striatum, indicating it acts as a D2 receptor antagonist.[2]

Ciclindole
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • N,N-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC14H18N2
Molar mass214.312 g·mol−1
3D model (JSmol)
  • c21c(cccc1)[nH]c3c2CC(N(C)C)CC3

Synthesis
Cyclindole synthesis: Aram Mooradian; Sterling Drug Inc. U.S. Patent 3,959,309

See also

References
  1. Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  2. Wood PL, McQuade PS (1984). "Ciclindole and flucindole: novel tetrahydrocarbazolamine neuroleptics". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 8 (4–6): 773–7. doi:10.1016/0278-5846(84)90057-5. PMID 6152347. S2CID 39252411.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.